Overview

Relative Bioavailability Study With BMS-955176

Status:
Completed

Trial end date:
2014-07-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to select the best dose level (amount of drug given) and best formulation of the study drug (BMS-955176) to develop further.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb
ViiV Healthcare

Collaborator:

GlaxoSmithKline

Treatments:

BMS-955176